Japan · Biotechnology startup
Japan · TMS
A Tokyo-based clinical-stage biotech company.
Funding reportedLast round: Undisclosed round
About TMS
A Tokyo-based clinical-stage biotech company.
Lead program TMS-007 (acute ischemic stroke) is partnered with Biogen.
What company datasets say TMS raised
Funding, as reported
Reported in all910.3Min the source's currency
Rounds4
Last roundUndisclosed round
Last round dateJun 2017
Investors listed11
On a portfolio page
Investors who name them
Each firm lists TMS on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Japan
Startups like it
Is this your company?
Add your raise, your deck and your story, and put TMS in front of investors. Or tell us what we have wrong.